Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. today announced that interim findings were presented from a Phase 1b clinical trial with atacicept in B-cell chronic lymphocytic leukemia (B-CLL) at the American Society of Clinical Oncology (ASCO) 2007 annual meeting. The study included intravenous administration of higher doses than had been tested in previous studies.

"We found that atacicept was well-tolerated and biologically active at all dose levels in this study, consistent with the results of our other clinical trials," said Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer of ZymoGenetics. "Together with our partner Merck Serono, we will assess the results of this and our other B-cell malignancy studies, once the studies are complete, to see whether the data support moving forward in these indications."

Atacicept in B-CLL Study Design and Results

In a Phase 1b open-label, dose escalation study, 15 patients with refractory or relapsed disease were given weekly intravenous doses of atacicept ranging from 1 mg/kg to 20 mg/kg, for five weeks. Treatment with atacicept was well tolerated at all dose levels in the study. No dose limiting toxicities or serious adverse events related to study drug have been reported to date. Among the six patients given 10 mg/kg and 15 mg/kg, three (50%) showed signs of disease stabilization, using National Cancer Institute-sponsored Working Group criteria, during the treatment period. Prior to atacicept treatment, all of these patients had rapidly increasing leukocyte counts. One patient, who received 10 mg/kg, exhibited stable disease for over six months.

Biological activity of atacicept was demonstrated in these patients by reduced immunoglobulin (Ig) concentrations after treatment at all dose levels. Mean IgA, IgG and IgM concentrations decreased by 20%, 22% and 15% from baseline, respectively, af
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, LLC ... Pharmaceutical Specialties, Inc. ("PSI").  The combination of Texas ... Georgia -based PSI bring together both company,s clinical expertise ... and payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... More than ... Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. ... for area students and operating support to UNCF-member institutions, including Miles College, Oakwood ...
(Date:12/2/2016)... ... , ... Center for Autism and Related Disorders (CARD) Portland today announced plans ... (ASD) and other developmental disabilities. The group, which is being launched with the help ... opportunity to share stories and advice, seek help, and continue their education on how ...
(Date:12/2/2016)... , ... December 02, 2016 , ... With the number ... rehabilitation of an injury, patients must find the one that works for them. When ... he created a machine that worked and decided to share it with others. , ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of ... 84 percent of parents report speaking with their child about sex related topics, less ... diseases. , Mediaplanet is proud to announce the launch of its second edition of ...
(Date:12/2/2016)... ... 2016 , ... The PAINWeekEnd Regional Conference will be hosted ... Honolulu, offering local frontline clinicians the opportunity to extend their certified continuing medical ... supplemental training related to pain management has surged dramatically in recent years, with ...
Breaking Medicine News(10 mins):